Blood Protein FAP Measured in Rheumatoid Arthritis and Systemic Sclerosis
Measures a blood protein linked to scarring in people with arthritis or systemic sclerosis.
Plain-language title generated from the registry record
Registry title: Correlation Between Circulating Fibroblast Activation Protein (FAP) and Fibrosis in Two Diseases (Rheumatoid Arthritis and Systemic Sclerosis)
Key facts
- Where
- Sohag, EgyptSee the site
Where in Egypt
- Sohag University HospitalSohag, EgyptNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sohag University
- Trial code
- NCT07393217
- Record updated
- 6 February 2026
- Original description
This study aims to measure a blood protein called fibroblast activation protein (FAP), which is linked to tissue scarring and inflammation. A small blood sample will be taken from participants (RA , SSc patients and healthy people ), and the FAP level will be measured and compared with routine clinical examinations, imaging studies, and lung function tests.Read full original descriptionShow less
Circulating Fibroblast Activation Protein (FAP) As A Marker for Fibroblast-Driven Pathology in Rheumatoid Arthritis and Systemic Sclerosis : Implication for Joint, Skin and Lung Fibrosis
This study aims to measure a blood protein called fibroblast activation protein (FAP), which is linked to tissue scarring and inflammation. A small blood sample will be taken from participants (RA , SSc patients and healthy people ), and the FAP level will be measured and compared with routine clinical examinations, imaging studies, and lung function tests.
The purpose of this study is to improve understanding of disease activity and lung involvement in these conditions and to explore whether FAP could be useful as a blood marker for future patients. Participation in this study will not change the participant's usual medical care.
Inclusion: Age ≥18 years. Confirmed diagnosis of RA (ACR/EULAR) or SSc (ACR/EULAR); Ability and willingness to provide informed consent. Cooperative patient able to answer questions.
Exclusion: Active cancer or history of cancer within 5 years; Other major fibrotic systemic disease that could confound circulating FAP levels; Acute infection at time of sampling; Other autoimmune diseases; Patients under 18 years' old; Pregnancy or breastfeeding.